Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves Hemophilia B Second Gene Therapy.

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Reversing the toxic relationship with high doses of chemotherapy in oncology.

4.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

5.

Durvalumab Wins FDA Approval in Limited-Stage SCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot